Novartis profit and sales forecast to decline in Q1 2026 amid generic competition
Updated
Updated · MarketWatch · Apr 27
Novartis profit and sales forecast to decline in Q1 2026 amid generic competition
9 articles · Updated · MarketWatch · Apr 27
Analysts expect Novartis to report Q1 2026 core operating profit of $5.1 billion and net sales of $13.34 billion, both down from last year.
The company faces pressure from generic rivals to key drugs like Entresto, Tasigna, and Promacta, with guidance signaling weakness in the first half of the year.
Novartis anticipates low single-digit net sales growth and a similar decline in core profit for 2026, while investors await updates on its drug pipeline and recently launched treatments.
With US drug price pressures mounting, can Novartis's new blockbusters maintain high profit margins?
Novartis's stock surged despite grim forecasts. Is the market overvaluing its pipeline or seeing a hidden turnaround?
As its heart drug trial ends, can Novartis win the race against newer, more convenient competitor therapies?
With key patents expiring, can new cancer drugs Pluvicto and Kisqali truly fill the massive revenue gap?
How will Novartis's multi-billion dollar acquisitions reshape its future beyond the current patent cliff?